An amazing drug test ends with all 18 cancer-free patients

18 бейтаптын баары раксыз дары-дармектердин сыноосу аяктады деген макала үчүн сүрөт

Photo: Dan Kitwood / Getty Images / Cancer Research UK) (Getty Images)

Cancer treatment has shown remarkable results in a small clinical trial. All treated patients with a specific form of mid-stage rectal cancer have since experienced complete remission. Although the studies are based on a sample size of 18 people, they may have significant results for the treatment of these particular cancers.

Results The second stage of the competition took place published New England Journal of Medicine over the weekend. The study, conducted by researchers at the Memorial Sloan Kettering Cancer Center and Yale University, was funded by the pharmaceutical company GlaxoSmithKline.

Volunteers were diagnosed with stage II or III rectal cancer, which means that their tumors have begun to grow and spread to nearby parts of the body. Their cancer is also caused by a specific mechanism called a Defects in improper repair.

Cancer can occur for a variety of reasons. However, sometimes mutations occur in our cells that prevent DNA from reproducing. These errors can eventually lead to cancer cells.

Researchers have suggested that their treatment, a laboratory-made antibody called Dostarlimab, could help this group of patients. It works by blocking a programmed lethal receptor-1 (PD-1) protein found in many cancer cells. This blockade allows the immune system to recognize the cancer cells as harmful and destroy them. The drug was developed by GlaxoSmithKline and supplied to it accelerated approval For cases of endometrial cancer due to lack of proper repair by the Food and Drug Administration last year.

Patients were given a dose of dostarlimab every three weeks for six months. Then, according to the initial plan, if their tumor is still found, they will be provided with standard chemotherapy and surgery. Surprisingly, the treatment alone seemed to have completely eradicated their cancer. At the time the study was published, 18 patients had completed treatment and 12 had been observed at least once. in, and none of them showed signs of cancer.

Cancer is known to be resistant to treatment, and few people have shown any success if any medication is observed here. “I think this is the first time in the history of cancer,” study author Louis A. Diaz Jr. said. Memorial Sloan is a staff member at the Kettering Cancer Center awning New York Times. According to the New York Times, the first patient to receive medication was diagnosed with cancer two years later.

That said, the findings are still early and more research is needed to confirm the efficacy of the drug, especially in the long term. Dostarlimab and similar immunotherapy treatments also have no side effects and they can rarely cause serious complications such as muscle weakness, but no such adverse events have been reported in this trial. The drug, however, is not cheap, costing $ 11,000 per dose out of pocket.

However, if these findings are confirmed, they could lead to a new standard of care for these types of cancer. Inadequate repair is often associated with colorectal cancer, but it can lead to breast, thyroid, bladder and prostate cancer, among others. The results show that if PD-1 inhibitors are used early in the development of cancer in people with this tumor, it can help them avoid severe treatment before it spreads to the body.


Leave a Comment

Your email address will not be published.